Hodi designed this investigator - initiated clinical trial to find out if giving sargramostim
along with
ipilimumab would have a synergistic effect against the melanoma — like pressing the immune system's accelerator while releasing the brake.
A University of California at Los Angeles (UCLA) study headed by Antoni Ribas, M.D., Ph.D., is a first - in - human phase I clinical trial combining adoptive cell transfer of a T cell receptor engineered to recognize NY - ESO - 1
along with Yervoy ® (
ipilimumab, anti-CTLA-4).